Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Indivior ( (INDV) ) has provided an update.
Indivior reported its third-quarter 2025 financial results, showing a 2% year-over-year increase in total net revenue to $314 million, driven by a 15% rise in SUBLOCADE’s net revenue. The company has raised its full-year 2025 financial guidance, expecting significant growth in adjusted EBITDA. Indivior is optimizing its Rest of World business by exiting several non-U.S. markets and plans to redomicile in the U.S. These strategic moves are expected to generate substantial operating expense savings and improve cash generation starting in 2026.
The most recent analyst rating on (INDV) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.
Spark’s Take on INDV Stock
According to Spark, TipRanks’ AI Analyst, INDV is a Neutral.
Indivior’s overall stock score is driven by strong earnings call performance and positive corporate events, offset by financial instability and lack of technical analysis data. The company’s strategic initiatives and improved guidance provide a positive outlook, but financial and valuation concerns remain.
To see Spark’s full report on INDV stock, click here.
More about Indivior
Indivior PLC operates in the pharmaceutical industry, focusing on addiction treatment products. Its primary products include SUBLOCADE, a treatment for opioid use disorder, and SUBOXONE Film, a buprenorphine/naloxone sublingual film. The company is focused on expanding its market presence in the U.S. and optimizing its operations globally.
Average Trading Volume: 2,533,928
Technical Sentiment Signal: Buy
Current Market Cap: $3.15B
Find detailed analytics on INDV stock on TipRanks’ Stock Analysis page.